BRIDGEWATER, N.J., Nov. Thirty (HSMN NewsFeed) — sanofi-aventis U.S. announced today the signing of an exclusive licensing agreement with Intelliject, Inc. for a novel epinephrine auto injector for the emergency treatment of allergic reactions (anaphylaxis)…
Devices, Biopharmaceuticals, Drug Delivery, Licensing
sanofi-aventis, Intelliject, epinephrine, injector

If you are a sales professional or want to become one, or if you are looking for a new sales job, you will face one of the toughest interview processes of any job seeker.
0 Comments on “sanofi-aventis U.S. and Intelliject, Inc. Sign Licensing Agreement for Novel Epinephrine Auto Injector in North America”
Leave a Comment